Yvonne Greenstreet
Yvonne Greenstreet has served as Chief Executive Officer of Alnylam since January 2022, having joined the company in 2016. Under her leadership, Alnylam has continued to advance RNAi therapeutics, achieving FDA approval for AMVUTTRA and transforming into a commercial company with successful product launches. She has also fostered an exceptional workplace culture, earning Alnylam recognition as a socially responsible company.
Career Milestones
- Joined Alnylam in 2016 as Chief Operating Officer and was appointed CEO in late 2021.
- Transformed Alnylam into a fully integrated commercial company, launching five products in four years.
- Oversaw the creation of Alnylam’s commercial capabilities and secured $2.2 billion in financing to support growth.
- Led the FDA approval of AMVUTTRA, advancing RNAi therapeutics into new therapeutic areas.
- Held senior leadership roles at Pfizer (2006–2011) and GlaxoSmithKline (2011–2016), contributing over 25 years of experience in the biopharmaceutical industry.
- Recognized as the Healthcare Businesswomen’s Association 2024 Woman of the Year for her leadership in diversity and women’s advancement in healthcare.
- Continues to drive Alnylam’s mission of delivering transformative RNAi medicines to patients worldwide.
About Alnylam
Alnylam is a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics, a revolutionary approach that "silences" genes causing or contributing to diseases. The company serves patients with rare and prevalent genetic diseases, focusing on areas of high unmet medical need. Alnylam's differentiator lies in its over two decades of innovation and leadership in developing this groundbreaking class of medicines.